Results 61 to 70 of about 4,608 (197)

Gold Nanoparticles Loaded With Lutetium‐177 Labeled DOTA‐TATE Exhibit Superior AR42J Cell Affinity and Extended Blood Circulation in AR42J Tumor Xenografts

Nano Select, Volume 7, Issue 2, February 2026.
The present study reports the development of a gold nanoparticle‐based delivery system functionalized with the established radiopharmaceutical [177Lu]Lu‐DOTA‐TATE. This design aims to enhance tumor‐targeting efficacy and improve the overall in vivo pharmacokinetic profile. In vitro studies demonstrated enhanced specificity toward somatostatin receptor (
Dheeraj Kumar, Rani Gnanasekar, Sheela Muralidharan, Shubhangi Mirapurkar, Krishna Mohan Repaka, Anupam Mathur, Madhava B. Mallia   +6 more
wiley   +1 more source

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Frontiers in Oncology, 2019
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs ...
Pashtoon Murtaza Kasi, Catherine L. Maige, Faisal Shahjehan, Jessica M. Rodgers, Debora L. Aloszka, Ashton Ritter, Margaret L. Andrus, Jessica M. Mcmillan, Kabir Mody, Akash Sharma, Manoj K. Jain   +10 more
doaj   +1 more source

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

Frontiers in Endocrinology, 2021
IntroductionPrimary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible.
Alexis Huot Daneault, Mélanie Desaulniers, Jean-Mathieu Beauregard, Alexis Beaulieu, Frédéric Arsenault, Geneviève April, Éric Turcotte, François-Alexandre Buteau   +7 more
doaj   +1 more source

Indications for Surgical Resection in Patients With Neuroendocrine Tumor Liver Metastases: An Intensive Surgical Experience of a High‐Volume Center

Annals of Gastroenterological Surgery, Volume 10, Issue 1, Page 219-228, January 2026.
In patients with NELM, those with < 8 liver metastases and G1/2 tumors are the favorable candidates for liver resection. The important point of this study is that the patients who do not meet the above criteria should be considered for multidisciplinary treatment because of their extremely shorter recurrence‐free period.
Daisuke Asano, Toshitaka Sugawara, Keiichi Akahoshi, Shotaro Gan, Shohei Motohashi, Shuichi Watanabe, Yoshiya Ishikawa, Hiroki Ueda, Atsushi Kudo, Daisuke Ban   +9 more
wiley   +1 more source

Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS) [PDF]

, 2021
Mina Swiha, Duncan E. K. Sutherland, Golmehr Sistani, Alireza Khatami, Rami M. Abazid, Amol Mujoomdar, Daniele Wiseman, Jonathan Romsa, Robert H. Reid, David Laidley   +9 more
openalex   +1 more source

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts [PDF]

Journal of Nuclear Medicine, 2015
The Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins University convened to cosponsor the Third Theranostics World Congress on Gallium-68 and PRRT, a conference held March 12–14, 2015, on the Johns Hopkins Medical Campus in Baltimore.
Richard P, Baum, Richard L, Wahl
openaire   +2 more sources

Accuracy and precision of few‐time‐points renal dosimetry for [177Lu]Lu‐PSMA‐617 therapy: Analysis with nonlinear mixed‐effects modeling

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background Determination of time‐integrated activity (TIA) with a reduced number of imaging sessions is essential for minimizing patient burden and clinical workload in the dosimetry of [177Lu]Lu‐PSMA‐617. One approach to achieve this is by performing single‐time‐point (STP) dosimetry.
Assyifa R. Hakim, Deni Hardiansyah, Elham Yousefzadeh‐Nowshahr, Ursula Nemer, Rien Ritawidya, Felix Kind, Ambros J. Beer, Philipp T. Meyer, Gerhard Glatting, Michael Mix   +9 more
wiley   +1 more source

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BMC Cancer, 2019
Background NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET.
S. Rudisile, A. Gosewisch, V. Wenter, M. Unterrainer, G. Böning, F. J. Gildehaus, W. P. Fendler, C. J. Auernhammer, C. Spitzweg, P. Bartenstein, A. Todica, H. Ilhan   +11 more
doaj   +1 more source